A Quality Improvement Project to Increase Utilization of an Urgent Care Clinic for Cancer.

Background: Nationally, patients with cancer experience high numbers of emergency department (ED) visits. Many ED visits may be prevented using cancer-specific urgent care services.

Objectives: The purpose of this quality improvement initiative was to first assess the reasons that adult patients with cancer used the ED instead of an urgent care clinic for cancer (UCC-C).

Beyond Kayaking - A qualitative investigation of parents and facilitators views regrading an outdoor, activity-based, multi-session parenting intervention program.

The Beyond Kayaking program is a free, outdoor activity-based, parenting intervention delivered across multiple sessions to vulnerable families in regional South Australia. Current literature on outdoor activity-based interventions have demonstrated improvements in family communication, problem-solving, bonding and trust. However, these studies are mostly based on single session interventions from the United States.

Antenatal Dads and First Year Families program: a qualitative study of fathers' and program facilitators' experiences of a community-based program in Australia.

Aim: Currently, there is limited knowledge on the impact of father-only sessions or parenting programs supporting impending fatherhood. This research explored an antenatal dads program aimed at fathers to assess the benefits of such interventions.

Background: Literature regarding parenting programs and early childhood education initiatives, especially those aimed at children and families in disadvantaged circumstance, have been demonstrated to act as a buffer to poorer health and lifestyle outcomes in later life.

Phase 2 study of CHOP-R-14 followed by Y-ibritumomab tiuxetan in patients with previously untreated diffuse large B-cell lymphoma.

The aim of this open-label, single-center, phase 2 study was to assess the efficacy and safety of dose-dense CHOP-R-14 followed by Y-ibritumomab radioimmunotherapy (RIT) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL). A total of 20 patients, the majority presenting with high-risk characteristics, were enrolled to receive dose-dense cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab every 14 days (CHOP-R-14), followed by Y-ibritumomab tiuxetan consolidation. Sixteen patients completed RIT consolidation (rituximab 250 mg/m on day 1 and day 7, 8, or 9, followed by a single injection of Y-ibritumomab).

Moderate dietary supplementation with vitamin E enhances lymphocyte functionality in the adult cat.

This study aimed to determine the effects of supplemental Vit E and/or Se on selected parameters of the immune system of the cat. Nine diets were fed in a 3 × 3 factorial design with no supplementation (control (C)); and either moderate (M); or high (H) levels of Vit E (0, 225 or 450 mg/kg DM diet) and/or Se (0, 2 or 10 mg/kg DM diet) added to a complete and balanced basal diet. After 28 days of feeding, enhanced lymphocyte proliferative responses to Concanavalin A and phytohaemagglutinin were observed (P < 0.

Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma.

Granulocyte-macrophage colony stimulating factor (GM-CSF) has been shown to enhance CD20 antigen expression, augment antibody-dependent cell-mediated cytotoxicity, and stimulate immune cell proliferation. This may lead to an improved anti-tumor effect of rituximab while reducing the severity of chemotherapy-induced myelosuppression. We evaluated the safety and efficacy of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in sequential combination with GM-CSF priming and rituximab in previously untreated patients (n = 39) with diffuse-large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL).

Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma.

Background: We conducted a single-institution phase II clinical trial evaluating the safety and efficacy of combination chemoimmunotherapy followed by radioimmunotherapy consolidation and rituximab maintenance as front-line treatment in indolent lymphomas.

Patients And Methods: We enrolled 20 patients with intermediate- to high-risk follicular lymphoma and 2 patients with marginal zone lymphoma. Treatment consisted of 4-6 cycles of FM (fludarabine 25 mg/m(2) on days 1-3, mitoxantrone 12 mg/m(2) on day 1 of each 28-day cycle).

Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.

Background: We evaluated the efficacy and safety of adding rituximab to nonanthracycline ESHAP (etoposide/methylprednisolone/cytarabine/cisplatin) chemotherapy for relapsed/refractory aggressive non-Hodgkin lymphoma (NHL).

Patients And Methods: Patients with intermediate- or high-grade NHL were to receive 6 rituximab doses and 6 ESHAP cycles. Rituximab 375 mg/m(2) was administered 1 week and 1 day before cycle 1 of standard ESHAP (etoposide 40 mg/m(2) on days 1-4; methylprednisolone 500 mg/m(2) on days 1-5; cytarabine 200 mg/m(2) on day 5; and cisplatin 25 mg/m(2) on days 1-4).

Patient-specific vaccine therapy for non-Hodgkin lymphoma.

Follicular non-Hodgkin lymphoma (NHL) is an indolent, or slow-growing, malignant disease of the lymphoid tissue, which usually responds to initial therapy. However, the disease is characterized by multiple relapses and remissions, eventually causing death. Several effective therapies are available, but improvement of overall survival in patients with follicular NHL has not been demonstrated.

Current therapeutic approaches in the treatment of Non-Hodgkin's lymphoma.

Objectives: To review the causes, classification, treatment, and new treatment modalities of non-Hodgkin's lymphoma.

Data Sources: Published literature and experimental therapies.

Conclusions: The increasing incidence of non-Hodgkin's lymphoma can be attributed to a growth in the number of immunodeficiency and autoimmune disorders, infectious agents, and human T-cell leukemia-lymphoma virus.